Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
News & Analysis: Rigel Pharmaceuticals
Duking it out in two immune-related diseases, these biotechs couldn’t be more different.
The pharmaceutical stock is surging after providing preliminary results for the fourth quarter of 2019.
The real question is whether growing product sales can outpace increasing R&D expenses.
RIGL earnings call for the period ending September 30, 2019.
The cheap biotech is showing signs of growth.
Investors cheered the latest business update, including a surprise move into an exciting area of research.
RIGL earnings call for the period ending June 30, 2019.
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
RIGL earnings call for the period ending March 31, 2019.